(2S)-2-methyl-5-(tert-butoxycarbonylamino)valeric acid | 1352407-83-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (2S)-2-methyl-5-(tert-butoxycarbonylamino)valeric acid
• 英文别名: Boc-(S)-5-amino-2-methylpentanoic acid；(S)-5-((tert-Butoxycarbonyl)amino)-2-methylpentanoic acid；(2S)-2-methyl-5-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid
• CAS: 1352407-83-0
• 化学式: C₁₁H₂₁NO₄
• 分子量: 231.292
• InChiKey: OBZVEXKLKXLILY-QMMMGPOBSA-N

物化性质

• 沸点：
  374.0±25.0 °C(Predicted)
• 密度：
  1.063±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (S)-5-((R)-4-benzyl-2-oxooxazolidin-3-yl)-4-methyl-5-oxopentanenitrile 在 platinum(IV) oxide 、 氢气 、 sodium hydroxide 、 lithium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 水 为溶剂， 20.0 ℃ 、344.75 kPa 条件下， 反应 29.0h， 生成 (2S)-2-methyl-5-(tert-butoxycarbonylamino)valeric acid
  参考文献：
  名称：

  Conformationally restricted analogs of the direct thrombin inhibitor FM 19

  摘要：

  The serine protease thrombin plays several key roles in the clotting cascade within the hemostatic system, such as in fibrin formation and platelet activation. Thus, development of an inhibitor that binds to the enzyme's active site (a direct thrombin inhibitor) offers an approach for the treatment of thrombus-associated diseases. Previous structure-activity relationship studies originally based on the bradykinin breakdown product Arg-Pro-Pro-Gly-Phe (RPPGF) led to the development of lead compound FM 19 (D-Arg-Oic-Pro-D-Ala-Phe(p-Me)-NH2). The recently determined X-ray structure of FM 19 in the active site of thrombin has revealed sites of modification to potentially improve inhibition. In this study, we report the synthesis and biological characterization of nine peptides that replace only the D-Arg residue of the FM 19 sequence, investigating ways to add conformational restriction, modification of the basic moiety at the end of the side chain, and removal of the charge from the N-terminus. Two of these peptides, 6 and 7 (IC50 values of 0.51 and 0.45 mu M, respectively), show similar potency to the best compounds in the FM 19 series reported thus far. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.10.045

文献信息

• BACTERIAL EFFLUX PUMP INHIBITORS
  申请人：Rutgers, The State University of New Jersey

  公开号：US20160271081A1

  公开（公告）日：2016-09-22

  Disclosed herein are compounds of formula I: and salts thereof. Also disclosed are compositions comprising of compounds of formula I and methods using compounds of formula I.

  本公开的是式I的化合物及其盐。还公开了包含式I化合物的组合物和使用式I化合物的方法。
• Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
  申请人：THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH

  公开号：US10039809B2

  公开（公告）日：2018-08-07

  Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.

  提供了延长治疗剂半衰期的方法和组合物。改性治疗剂（mTA）由治疗剂、主食和延长半衰期分子组成。本文公开的 mTA 可用于治疗有需要的受试者的疾病或病症。
• Modulation of the Passive Permeability of Semipeptidic Macrocycles: N- and C-Methylations Fine-Tune Conformation and Properties
  作者：Christian Comeau、Benjamin Ries、Thomas Stadelmann、Jacob Tremblay、Sylvain Poulet、Ulrike Fröhlich、Jérôme Côté、Pierre-Luc Boudreault、Rabeb Mouna Derbali、Philippe Sarret、Michel Grandbois、Grégoire Leclair、Sereina Riniker、Éric Marsault

  DOI：10.1021/acs.jmedchem.0c02036

  日期：2021.5.13
• RGD-CONTAINING CYCLIC PEPTIDES
  申请人：Lam Kit S.

  公开号：US20130172270A1

  公开（公告）日：2013-07-04

  The present invention is drawn to cyclic RGD peptides linked via a disulfide bond, where the terminal cysteines are preferably in the D configuration. These peptides target αvβ3 integrin on tumor cells and neovasculatures and function as targeting agents for tumor diagnostic imaging and therapy. Compared with the commonly used RGD ligands, compounds of the present invention have improved targeting efficacy and lower nonspecific binding to normal organs. Moreover, the compounds of the present invention can be functionalized to conjugate imaging payload without decreasing binding strength.
• MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF
  申请人：THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH

  公开号：US20160317623A1

  公开（公告）日：2016-11-03

  Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.